TY  - JOUR
AU  - Eskilsson, Eskil
AU  - Røsland, Gro V
AU  - Solecki, Gergely Morten
AU  - Wang, Qianghu
AU  - Harter, Patrick N
AU  - Graziani, Grazia
AU  - Verhaak, Roel G W
AU  - Winkler, Frank
AU  - Bjerkvig, Rolf
AU  - Miletic, Hrvoje
TI  - EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
JO  - Neuro-Oncology
VL  - 20
IS  - 6
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2022-01995
SP  - 743 - 752
PY  - 2018
N1  - POT Topic: 317
AB  - Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets.
KW  - ErbB Receptors: antagonists & inhibitors
KW  - ErbB Receptors: genetics
KW  - Glioblastoma: drug therapy
KW  - Glioblastoma: genetics
KW  - Glioblastoma: pathology
KW  - Humans
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Prognosis
KW  - Protein Kinase Inhibitors: therapeutic use
KW  - Protein Kinase Inhibitors (NLM Chemicals)
KW  - EGFR protein, human (NLM Chemicals)
KW  - ErbB Receptors (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:29040782
C2  - pmc:PMC5961011
DO  - DOI:10.1093/neuonc/nox191
UR  - https://inrepo02.dkfz.de/record/181427
ER  -